September 15, 2021
2 min learn
NIH, Cancer Prevention Analysis Institute of Texas and Susan G. Komen grants supported the examine. Nead experiences no related monetary disclosures. Please see the examine for all different authors’ related monetary disclosures.
Use of statin remedy throughout the first 12 months after breast cancer analysis appeared related with a survival profit amongst women with stage I to stage III triple-negative breast cancer, in line with examine outcomes printed in Cancer.
“There’s a wealth of prior analysis on statins and breast cancer with inconsistent outcomes. Nonetheless, there was restricted analysis on statins and essentially the most aggressive types of breast cancer, particularly triple-negative breast cancer,” Kevin T. Nead, MD, MPhil, researcher within the division of epidemiology and division of cancer prevention and inhabitants sciences at The College of Texas MD Anderson Cancer Heart, informed Healio. “We have been concerned with whether or not there was an affiliation between beginning statin therapy throughout the 12 months following a analysis of breast cancer and improved survival amongst sufferers with triple-negative breast cancer.”
Nead and colleagues used knowledge from the SEER-Medicare and Texas Cancer Registry-Medicare databases between 2008 and 2015 to retrospectively consider 23,192 women aged 66 years and older with stage I to stage III breast cancer.
Roughly three-quarters (78.1%; n = 2,281) of women included within the examine had initiated statin remedy inside 1 12 months after analysis.
Researchers used multivariable Cox proportional hazards regression fashions to evaluate the affiliation of latest statin remedy use inside 1 12 months after breast cancer analysis with OS and breast cancer-specific survival.
Median follow-up was 4.4 years (vary, 1-10) for OS and three.3 years (vary, 0.1-8) for breast cancer-specific survival.
Nead and colleagues noticed a major affiliation between incident statin use and enhancements in breast cancer-specific survival (standardized HR [sHR] = 0.42; 95% CI, 0.2-0.88) and OS (HR = 0.7; 95% CI, 0.5-0.99) amongst women with triple-negative breast cancer (n = 1,534).
Conversely, outcomes confirmed no affiliation of statin use with breast cancer-specific survival (sHR = 0.99; 95% CI, 0.71-1.39) or OS (HR = 1.04; 95% CI, 0.92-1.17) amongst women with different breast cancer subtypes (n = 15,979).
Researchers additionally discovered a major affiliation particularly between lipophilic statin use and enhancements in OS (HR = 0.66; 95% CI, 0.45-0.97) — with a directionally constant influence on breast cancer-specific survival (sHR = 0.5; 95% CI, 0.24-1.07) — amongst women with triple-negative breast cancer. Excessive-intensity statin remedy appeared to have the best impact on OS among the many triple-negative breast cancer group (HR = 0.25; 95% CI, 0.06-1.01), however inadequate occasions occurred to look at breast cancer-specific survival on this subset.
Kevin T. Nead
“The big magnitude of improved survival for sufferers beginning a statin inside 1 12 months of analysis was shocking,” Nead stated. “The essential science and observational knowledge make a strong case that statins may benefit sufferers with triple-negative breast cancer. The mixture of extra restricted efficient remedy choices for triple-negative breast cancer and the low toxicity profile of statin remedy makes the potential use of statins as an adjuvant remedy in triple-negative breast cancer a compelling analysis query we should always proceed to pursue.
“The following step is to confirm our findings utilizing the same examine design in a comparable knowledge set,” Nead added “If the outcomes maintain up, an affordable subsequent step is to pursue a scientific trial to formally take a look at whether or not beginning statin remedy throughout the 12 months after analysis of triple-negative breast cancer improves affected person outcomes.”
For extra data:
Kevin T. Nead, MD, MPhil, might be reached at The College of Texas MD Anderson Cancer Heart, 1515 Pressler St., Workplace CPB4.3275, Houston, TX 77030; e-mail: email@example.com.